Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 22, 2023 07:00 ET | Source: Arch Biopartners

Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

TORONTO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that it has submitted applications to the Ministry of...
July 28, 2020 08:13 ET | Source: Arch Biopartners

Broward Health Medical Center Becomes First Clinical Site in U.S. for Phase II Trial for LSALT Peptide

TORONTO, July 28, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
July 14, 2020 07:00 ET | Source: Arch Biopartners

Arch Biopartners Engages Global CRO to Conduct LSALT peptide (Metablok) Phase II trial for Treatment of Complications in COVID-19 Patients in the U.S.

Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in Patients Infected with...
June 30, 2020 09:21 ET | Source: Arch Biopartners

Arch Biopartners Closes Non-Brokered Private Placement

TORONTO, June 30, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...